Calculate exact reconstitution volumes, insulin units, and doses per vial for any peptide.
KPV is a synthetic tripeptide composed of three amino acids: lysine, proline, and valine. Its name is derived from the single-letter codes of those amino acids (K-P-V). KPV is the C-terminal fragment of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH) — specifically residues 11 through 13. While alpha-MSH is a much larger 13-amino-acid peptide that produces a broad range of effects, including pigmentation, appetite regulation, and inflammatory modulation, KPV isolates the anti-inflammatory portion of that molecule without the pigment-driving properties.
This is what makes KPV interesting in preclinical research: it is a small, comparatively stable molecule that carries the immunomodulatory signature of alpha-MSH without binding to the melanocortin receptors responsible for skin tanning. As a result, the literature frequently discusses KPV alongside peptides such as BPC-157 and Selank in the context of barrier function, mucosal repair, and anti-inflammatory activity. Unlike Melanotan compounds, which are also derived from the melanocortin family, KPV has no meaningful effect on pigmentation.
KPV is not a hormone in the classical sense and does not act on the hypothalamic-pituitary axis. It works predominantly at the local, cellular level, where it modulates inflammatory signaling pathways. Its low molecular weight allows researchers to study not only injectable administration but also oral and topical routes. The information presented here applies strictly to the research context; KPV is not an approved drug.
KPV exerts its biological activity primarily by dampening inflammatory signaling cascades. Unlike its parent peptide alpha-MSH, KPV appears to act largely independently of cell-surface receptors: research data suggest the tripeptide is taken up into the cell and intervenes in key signaling pathways intracellularly rather than docking onto an external receptor. The effects described in the preclinical literature include:
KPV does not typically require a titration ramp. Most research protocols use a fixed daily dose. Because it is a small tripeptide with a short half-life, some protocols use once-daily administration while others split the dose into two applications per day.
A common vial size is 5 mg. Adding 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL (2,500 mcg/mL).
At 250 mcg once daily, a 5 mg vial provides 20 days of dosing. Use the KPV calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose. The calculator is also helpful when using a 10 mg vial, since concentration and syringe volume shift accordingly.
KPV is supplied as a lyophilized (freeze-dried) powder in sealed vials. For injectable use it must be reconstituted with bacteriostatic water (BAC water) before application. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection should not be used for multi-dose vials because it contains no preservative.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it. The oral and topical routes also studied in research use different preparations that are outside the scope of this injection-focused guide.
KPV is regarded as a well-tolerated peptide in preclinical research. As a short tripeptide and a fragment of an endogenous hormone, it has not shown a pronounced toxicity profile in animal models. Robust human clinical trials are largely absent, however, which is why use remains strictly within the research domain and all statements should be assessed with appropriate caution.
No serious adverse events have been attributed to KPV in the published literature at standard research doses. Given the absence of large-scale human trials, caution is warranted and consultation with a qualified healthcare professional is strongly recommended.
KPV is frequently considered alongside BPC-157 in research on the gastrointestinal barrier. The two peptides address complementary aspects: BPC-157 is one of the most extensively studied peptides for gastrointestinal repair and drives angiogenesis and mucosal healing, while KPV specifically dampens the inflammatory component through inhibition of NF-kB. In preclinical gut models, the regenerative orientation of BPC-157 complements the anti-inflammatory profile of KPV. View detailed dosing information for BPC-157 at the BPC-157 calculator.
Another combination discussed in research pairs KPV with Selank. Selank is studied primarily in the context of stress regulation and neuroimmune modulation. While KPV acts on the peripheral inflammatory burden, Selank addresses overlapping pathways at the neuroimmune level. Research protocols that combine both peptides treat them as two independent tools with separate focal points.
In the broader immunological context, KPV is also positioned alongside Thymosin Alpha-1. Thymosin Alpha-1 is associated in research with the regulation of the immune response. The combination is of interest because KPV dampens inflammatory overactivation, while Thymosin Alpha-1 modulates immune balance at a different level. Each component should be reconstituted and dosed individually.
No. KPV is the C-terminal fragment of alpha-MSH and consists of only three amino acids, whereas alpha-MSH is a complete 13-amino-acid peptide hormone. KPV carries the anti-inflammatory portion of the molecule but lacks the pigment-driving properties of alpha-MSH, because it does not bind to the melanocortin receptors responsible for tanning.
Based on current research, no. Unlike Melanotan compounds, which are also derived from the melanocortin family, KPV has no meaningful effect on melanin production. Dermatological research on KPV focuses on inflammatory skin models and barrier function, not pigmentation.
In research, KPV is studied orally in addition to injectable use, particularly in gut models. Studies describe that KPV is taken up by intestinal epithelial cells via a peptide transporter, enabling a local effect in the gastrointestinal tract. For systemic research questions, subcutaneous administration is generally preferred.
Because KPV has primarily been studied in preclinical models, no reliable statements about human time windows can be made. The underlying mechanism — dampening inflammatory signaling — acts relatively quickly at the cellular level, but the observable effect depends heavily on the specific model and endpoint. Any timing outside controlled studies is speculative.
KPV is not a hormone in the functional sense and does not act on the hypothalamic-pituitary axis. Based on the current research, it does not bind to the classical melanocortin receptors and affects neither the sex hormones nor thyroid or adrenal function. Post-cycle therapy is not relevant.
KPV is typically offered in 5 mg and 10 mg vials. The 5 mg size is practical for most research protocols, as it covers roughly 20 days at a daily dose of 250 mcg. Larger vials reduce the number of reconstitution events but must be used within the shelf-life window of the reconstituted solution.
It is safer to reconstitute and inject each peptide individually. The combined stability of KPV and BPC-157 in a shared solution is not well characterized. Two separate injections at the same or an adjacent site add only minor inconvenience while eliminating the risk of interaction or concentration errors.
Verified purity is essential, ideally documented by a certificate of analysis (HPLC and mass spectrometry). Because KPV is a short peptide, synthesis byproducts can distort the actual activity profile. Also look for proper lyophilization and appropriate refrigerated logistics. KPV is offered strictly for research purposes.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. KPV is not an approved drug or medical treatment and is described strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.